When was ETHERNA IMMUNOTHERAPIES founded?

ETHERNA IMMUNOTHERAPIES was founded on 21 Jan 2013, making it 13 years old.

Is ETHERNA IMMUNOTHERAPIES still active?

Yes, ETHERNA IMMUNOTHERAPIES is currently active.

Where is ETHERNA IMMUNOTHERAPIES registered?

ETHERNA IMMUNOTHERAPIES's registered address is Galileilaan 19, 2845 Niel, Belgium.

How many employees does ETHERNA IMMUNOTHERAPIES have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2025), ETHERNA IMMUNOTHERAPIES reported 52.1 full-time equivalent employees.

What is ETHERNA IMMUNOTHERAPIES's annual turnover?

ETHERNA IMMUNOTHERAPIES's most recently filed annual turnover (fiscal year ending 31 Dec 2025) was €8,788,056.

Did ETHERNA IMMUNOTHERAPIES make a profit or a loss?

ETHERNA IMMUNOTHERAPIES's most recently filed annual accounts (fiscal year ending 31 Dec 2025) reported a loss of €4,271,721.

When did ETHERNA IMMUNOTHERAPIES last file annual accounts?

ETHERNA IMMUNOTHERAPIES's most recently filed annual accounts cover the fiscal year ending 31 Dec 2025.

Is ETHERNA IMMUNOTHERAPIES B Corp certified?

We have no B Corp certification on file for ETHERNA IMMUNOTHERAPIES.

Does ETHERNA IMMUNOTHERAPIES hold Fairtrade certification?

No, ETHERNA IMMUNOTHERAPIES does not currently hold Fairtrade certification.

ETHERNA IMMUNOTHERAPIES

Q: What is ETHERNA IMMUNOTHERAPIES's legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

Q: What does ETHERNA IMMUNOTHERAPIES do?

ETHERNA IMMUNOTHERAPIES's registered main activities are Research and experimental development on other natural sciences and engineering, Research and experimental development on biotechnology, Business and other management consultancy activities, Manufacture of other pharmaceutical products, and Manufacture of basic pharmaceutical products.

BE 0502.703.389

Copied!

NV/SA

Status

Active

Founded

21 Jan 2013

Size

Medium · 52.1 FTE

Age

13 yrs

Main activity

Research and experimental development on other natural sciences and engineering

Website

etherna.be

Activities

5 activities

Research and experimental development on other natural sciences and engineeringResearch and experimental development on biotechnologyBusiness and other management consultancy activitiesManufacture of other pharmaceutical productsManufacture of basic pharmaceutical products

Financials

Turnover2025

€8.8M-21.7%

Profit / Loss2025

−€4.3M+35.5%

Equity2025

−€3.9M<-1000%

2025	2024	2023	2022
€8,788,056-21.7%	€11,226,381+65.2%	€6,796,302+65.3%	€4,111,500
-€4,271,721+35.5%	-€6,623,923+38%	-€10,679,614+42.1%	-€18,453,870
-€3,907,881<-1000%	€349,455-95%	€6,973,378-60.5%	€17,652,992
€15,948,448+8.4%	€14,715,658+62.9%	€9,032,667+22.1%	€7,396,504
€2,417,919-4%	€2,517,887+10.4%	€2,280,940-83.6%	€13,943,394
52.1-25.5%	69.9+1.9%	68.6+7%	64.1
€168,677+5%	€160,606+62.1%	€99,071+54.5%	€64,142

Frequently asked questions

01What is ETHERNA IMMUNOTHERAPIES's official registered name?

ETHERNA IMMUNOTHERAPIES.

02What is ETHERNA IMMUNOTHERAPIES's enterprise number (VAT number)?

BE 0502.703.389.

03What is ETHERNA IMMUNOTHERAPIES's legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

	2025	2024	2023	2022
Income statement
	€8,788,056-21.7%	€11,226,381+65.2%	€6,796,302+65.3%	€4,111,500
	€4,585,644-33.3%	€6,872,240-8.5%	€7,514,727+19.3%	€6,298,658
	-€3,910,014+42.9%	-€6,842,369+36.9%	-€10,842,943+40.2%	-€18,124,411
	€1,919,508-4.6%	€2,012,426+140.7%	-€4,943,126	—
	€2,275,196	—	—	—
	-€4,271,721+35.5%	-€6,623,923+38%	-€10,679,614+42.1%	-€18,453,870
Profitability
	21.8%+21.9%	17.9%+124.7%	-72.7%	—
	-48.6%+17.6%	-59.0%+62.5%	-157.1%+65%	-448.8%
	109.3%+105.8%	-1895.5%<-1000%	-153.1%-46.5%	-104.5%
	-33.5%+23.9%	-44.0%+34.1%	-66.7%+9.4%	-73.7%
Solvency
	€12,757,962-15.3%	€15,065,113-5.9%	€16,006,045-36.1%	€25,049,496
	€1,623,934-33.4%	€2,440,278-22%	€3,130,615+2.5%	€3,053,367
	€3,044,2290%	€3,044,174+45.6%	€2,090,5130%	€2,090,327
	-€3,907,881<-1000%	€349,455-95%	€6,973,378-60.5%	€17,652,992
	-30.6%<-1000%	2.3%-94.7%	43.6%-38.2%	70.5%
	€224,562-36.3%	€352,614-20.3%	€442,553+148.8%	€177,897
	-0.06-105.7%	1.01>1000%	0.06+529.8%	0.01
	€15,948,448+8.4%	€14,715,658+62.9%	€9,032,667+22.1%	€7,396,504
	-4.08-109.7%	42.11>1000%	1.30+209.2%	0.42
	-8.32+96.2%	-219.54+46.6%	-411.01<-1000%	-25.79
Liquidity
	€2,417,919-4%	€2,517,887+10.4%	€2,280,940-83.6%	€13,943,394
	€1,385,869-28.4%	€1,936,775-19.8%	€2,413,629	—
	€258,157-21.3%	€327,989-78.8%	€1,545,309-6.5%	€1,653,188
	€2,600,078+1%	€2,573,480-13.1%	€2,960,307+0.5%	€2,946,605
	€8,684,006+97%	€4,407,903-6.9%	€4,733,415+6.3%	€4,454,264
	0.16-34.8%	0.24-59.9%	0.61+42.8%	0.43
	-€10,807,411-29.5%	-€8,345,281-664.6%	-€1,091,474-111.1%	€9,796,056
Efficiency
	11 days+0.6%	11 days-87.2%	83 days-43.4%	147 days
	144 days+53.9%	93 days-6.3%	100 days+62%	61 days
	211 days+9.8%	193 days-18.4%	236 days	—
	1.44-14.8%	1.69	—	—
Profit appropriation
	€6,1500%	€6,1500%	€6,1500%	€6,150
	-€29,617,350-16.8%	-€25,345,629-35.4%	-€18,721,706-132.8%	-€8,042,092

Sources

NBB — Nationale Bank van België

	2025	2024	2023	2022
Income statement
	€8,788,056-21.7%	€11,226,381+65.2%	€6,796,302+65.3%	€4,111,500
	€4,585,644-33.3%	€6,872,240-8.5%	€7,514,727+19.3%	€6,298,658
	-€3,910,014+42.9%	-€6,842,369+36.9%	-€10,842,943+40.2%	-€18,124,411
	€1,919,508-4.6%	€2,012,426+140.7%	-€4,943,126	—
	€2,275,196	—	—	—
	-€4,271,721+35.5%	-€6,623,923+38%	-€10,679,614+42.1%	-€18,453,870
Profitability
	21.8%+21.9%	17.9%+124.7%	-72.7%	—
	-48.6%+17.6%	-59.0%+62.5%	-157.1%+65%	-448.8%
	109.3%+105.8%	-1895.5%<-1000%	-153.1%-46.5%	-104.5%
	-33.5%+23.9%	-44.0%+34.1%	-66.7%+9.4%	-73.7%
Solvency
	€12,757,962-15.3%	€15,065,113-5.9%	€16,006,045-36.1%	€25,049,496
	€1,623,934-33.4%	€2,440,278-22%	€3,130,615+2.5%	€3,053,367
	€3,044,2290%	€3,044,174+45.6%	€2,090,5130%	€2,090,327
	-€3,907,881<-1000%	€349,455-95%	€6,973,378-60.5%	€17,652,992
	-30.6%<-1000%	2.3%-94.7%	43.6%-38.2%	70.5%
	€224,562-36.3%	€352,614-20.3%	€442,553+148.8%	€177,897
	-0.06-105.7%	1.01>1000%	0.06+529.8%	0.01
	€15,948,448+8.4%	€14,715,658+62.9%	€9,032,667+22.1%	€7,396,504
	-4.08-109.7%	42.11>1000%	1.30+209.2%	0.42
	-8.32+96.2%	-219.54+46.6%	-411.01<-1000%	-25.79
Liquidity
	€2,417,919-4%	€2,517,887+10.4%	€2,280,940-83.6%	€13,943,394
	€1,385,869-28.4%	€1,936,775-19.8%	€2,413,629	—
	€258,157-21.3%	€327,989-78.8%	€1,545,309-6.5%	€1,653,188
	€2,600,078+1%	€2,573,480-13.1%	€2,960,307+0.5%	€2,946,605
	€8,684,006+97%	€4,407,903-6.9%	€4,733,415+6.3%	€4,454,264
	0.16-34.8%	0.24-59.9%	0.61+42.8%	0.43
	-€10,807,411-29.5%	-€8,345,281-664.6%	-€1,091,474-111.1%	€9,796,056
Efficiency
	11 days+0.6%	11 days-87.2%	83 days-43.4%	147 days
	144 days+53.9%	93 days-6.3%	100 days+62%	61 days
	211 days+9.8%	193 days-18.4%	236 days	—
	1.44-14.8%	1.69	—	—
Profit appropriation
	€6,1500%	€6,1500%	€6,1500%	€6,150
	-€29,617,350-16.8%	-€25,345,629-35.4%	-€18,721,706-132.8%	-€8,042,092

2025

2024

2023

2022

Income statement

€8,788,056-21.7%

€11,226,381+65.2%

€6,796,302+65.3%

€4,111,500

€4,585,644-33.3%

€6,872,240-8.5%

€7,514,727+19.3%

€6,298,658

-€3,910,014+42.9%

-€6,842,369+36.9%

-€10,842,943+40.2%

-€18,124,411

€1,919,508-4.6%

€2,012,426+140.7%

-€4,943,126

—

€2,275,196

—

-€4,271,721+35.5%

-€6,623,923+38%

-€10,679,614+42.1%

-€18,453,870

Profitability

21.8%+21.9%

17.9%+124.7%

-72.7%

—

-48.6%+17.6%

-59.0%+62.5%

-157.1%+65%

-448.8%

109.3%+105.8%

-1895.5%<-1000%

-153.1%-46.5%

-104.5%

-33.5%+23.9%

-44.0%+34.1%

-66.7%+9.4%

-73.7%

Solvency

€12,757,962-15.3%

€15,065,113-5.9%

€16,006,045-36.1%

€25,049,496

€1,623,934-33.4%

€2,440,278-22%

€3,130,615+2.5%

€3,053,367

€3,044,2290%

€3,044,174+45.6%

€2,090,5130%

€2,090,327

-€3,907,881<-1000%

€349,455-95%

€6,973,378-60.5%

€17,652,992

-30.6%<-1000%

2.3%-94.7%

43.6%-38.2%

70.5%

€224,562-36.3%

€352,614-20.3%

€442,553+148.8%

€177,897

-0.06-105.7%

1.01>1000%

0.06+529.8%

0.01

€15,948,448+8.4%

€14,715,658+62.9%

€9,032,667+22.1%

€7,396,504

-4.08-109.7%

42.11>1000%

1.30+209.2%

0.42

-8.32+96.2%

-219.54+46.6%

-411.01<-1000%

-25.79

Liquidity

€2,417,919-4%

€2,517,887+10.4%

€2,280,940-83.6%

€13,943,394

€1,385,869-28.4%

€1,936,775-19.8%

€2,413,629

—

€258,157-21.3%

€327,989-78.8%

€1,545,309-6.5%

€1,653,188

€2,600,078+1%

€2,573,480-13.1%

€2,960,307+0.5%

€2,946,605

€8,684,006+97%

€4,407,903-6.9%

€4,733,415+6.3%

€4,454,264

0.16-34.8%

0.24-59.9%

0.61+42.8%

0.43

-€10,807,411-29.5%

-€8,345,281-664.6%

-€1,091,474-111.1%

€9,796,056

Efficiency

11 days+0.6%

11 days-87.2%

83 days-43.4%

147 days

144 days+53.9%

93 days-6.3%

100 days+62%

61 days

211 days+9.8%

193 days-18.4%

236 days

—

1.44-14.8%

1.69

—

Profit appropriation

€6,1500%

€6,150

-€29,617,350-16.8%

-€25,345,629-35.4%

-€18,721,706-132.8%

-€8,042,092

ETHERNA IMMUNOTHERAPIES

Activities

Financials

Frequently asked questions

All locations

All locations